Archived Bulletins

March 28, 2018

Published: March 28, 2018
Category: Trials

The MAC.23 trial a Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation with Breast Reconstruction has been centrally activated

Read More

Published: March 28, 2018
Category: Group updates

The Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has current job openings for two Study Coordinators and a Monitor/Auditor. Please visit our career page to find out more about these roles and how to apply.

Read More

Published: March 28, 2018
Category: Group updates
The Canadian Cancer Trials Group (CCTG) 2018 Annual Spring Meeting of Participants will be held April 27 - 29, 2018 at the Chelsea Hotel in Toronto.

Invitation Requests and Registration
Read More

Published: March 28, 2018
Category: Group updates

Reminder: Feedback request on Health Canada Guidance GUI-0100 due April 2, 2018

Read More

Congratulations to our colleague Dr. Frances Shepherd, medical oncologist at Princess Margaret Cancer Centre, who has received the prestigious 2018 Canada Gairdner Wightman Award "for her global leadership in oncology which has contributed significantly to the improving survival outcome of lung cancer patients worldwide." Dr. Shepherd served as Chair of the Lung Cancer Committee at CCTG for 19 years!

Read more about the award

Read More

Published: March 28, 2018
Category: Publications
IND210: A Randomized Phase II Study of Reolysin in Combination with FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients with Metastatic Colorectal Cancer
 
Read More

March 14, 2018

Dr. John Hilton, the Study Co-Chair of IND.231, gave an oral presentation

Dr. John Hilton, the Study Co-Chair of IND.231, gave an oral presentation of the results to date from IND.231, A Phase I/II Study of CX-5461, at the Targeted Anti-Cancer Therapies (TAT) International Congress 2018 - "the home of phase I in oncology". The conference was held in Paris, France on March 5-7, 2018.

TAT focuses on early-phase development and translational research. The programme covers targeted agents, immuno-oncology and combinations involving such agents.

Read More

Published: March 14, 2018
Category: Trials
CCTG IND.225  is a phase II study of the assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker, is closed to accrual.
Read More